Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
This PHASE2 trial investigates Thymic Epithelial Tumor and is currently ongoing. Shanghai Pulmonary Hospital, Shanghai, China leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
May 2025 — Present [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
May 2023 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — May 2023 [monthly]
Not Yet Recruiting PHASE2
▶ Show 1 earlier version
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Pulmonary Hospital, Shanghai, China
For direct contact, visit the study record on ClinicalTrials.gov .